Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|October 15, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 10
- Volume 18
- Issue 10
Bayer Taps New CEO
Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010.
Advertisement
Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010. Dr. Dekkers will join the company's board at the start of 2010 and will also serve as CEO of Bayer's healthcare division. He is currently president and CEO of Thermo Fisher Scientific.
Articles in this issue
almost 17 years ago
Cancer, not HPV vaccination, hastened death of UK girlalmost 17 years ago
Obesity hinders treatment in pediatric leukemiaalmost 17 years ago
Posaconazole reduces infection in AML patientsalmost 17 years ago
Global report warns of escalating cancer ratealmost 17 years ago
New class of alpha emitters takes aim at bone metastasesalmost 17 years ago
Who's Newsalmost 17 years ago
Stop and smell the volatile organic compounds in lung caalmost 17 years ago
Proton therapy report advises cautionAdvertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC
4
Sequencing CAR T-Cell Therapy and Bispecifics to Preserve T-Cell Fitness
5